BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 33029258)

  • 1. eRNAs and Superenhancer lncRNAs Are Functional in Human Prostate Cancer.
    Zhang X; Pang P; Jiang M; Cao Q; Li H; Xu Y; Li Y; Chen X; Han J
    Dis Markers; 2020; 2020():8847986. PubMed ID: 33029258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancer RNAs in cancer: regulation, mechanisms and therapeutic potential.
    Lee JH; Xiong F; Li W
    RNA Biol; 2020 Nov; 17(11):1550-1559. PubMed ID: 31916476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On the Origin of lncRNAs: Missing Link Found.
    Espinosa JM
    Trends Genet; 2017 Oct; 33(10):660-662. PubMed ID: 28778681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
    Mouraviev V; Lee B; Patel V; Albala D; Johansen TE; Partin A; Ross A; Perera RJ
    Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):14-20. PubMed ID: 26503110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EMX2OS plays a prognosis-associated enhancer RNA role in gastric cancer.
    Liu GX; Tan YZ; He GC; Zhang QL; Liu P
    Medicine (Baltimore); 2021 Oct; 100(41):e27535. PubMed ID: 34731149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional roles of antisense enhancer RNA for promoting prostate cancer progression.
    Pan CW; Wen S; Chen L; Wei Y; Niu Y; Zhao Y
    Theranostics; 2021; 11(4):1780-1794. PubMed ID: 33408781
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of androgen-responsive lncRNAs as diagnostic and prognostic markers for prostate cancer.
    Wan X; Huang W; Yang S; Zhang Y; Pu H; Fu F; Huang Y; Wu H; Li T; Li Y
    Oncotarget; 2016 Sep; 7(37):60503-60518. PubMed ID: 27556357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cis-acting lnc-eRNA SEELA directly binds histone H4 to promote histone recognition and leukemia progression.
    Fang K; Huang W; Sun YM; Chen TQ; Zeng ZC; Yang QQ; Pan Q; Han C; Sun LY; Luo XQ; Wang WT; Chen YQ
    Genome Biol; 2020 Nov; 21(1):269. PubMed ID: 33143730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNA: A newly deciphered "code" in prostate cancer.
    Zhang A; Zhang J; Kaipainen A; Lucas JM; Yang H
    Cancer Lett; 2016 Jun; 375(2):323-330. PubMed ID: 26965999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current Advances on the Important Roles of Enhancer RNAs in Molecular Pathways of Cancer.
    Wang R; Tang Q
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive characterization of functional eRNAs in lung adenocarcinoma reveals novel regulators and a prognosis-related molecular subtype.
    Qin N; Ma Z; Wang C; Zhang E; Li Y; Huang M; Chen C; Zhang C; Fan J; Gu Y; Xu X; Yang L; Wei X; Yin R; Jiang Y; Dai J; Jin G; Xu L; Hu Z; Shen H; Ma H
    Theranostics; 2020; 10(24):11264-11277. PubMed ID: 33042282
    [No Abstract]   [Full Text] [Related]  

  • 12. Insights into Enhancer RNAs: Biogenesis and Emerging Role in Brain Diseases.
    Shen Y; Huang Z; Yang R; Chen Y; Wang Q; Gao L
    Neuroscientist; 2023 Apr; 29(2):166-176. PubMed ID: 34612730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The long noncoding RNA landscape of neuroendocrine prostate cancer and its clinical implications.
    Ramnarine VR; Alshalalfa M; Mo F; Nabavi N; Erho N; Takhar M; Shukin R; Brahmbhatt S; Gawronski A; Kobelev M; Nouri M; Lin D; Tsai H; Lotan TL; Karnes RJ; Rubin MA; Zoubeidi A; Gleave ME; Sahinalp C; Wyatt AW; Volik SV; Beltran H; Davicioni E; Wang Y; Collins CC
    Gigascience; 2018 Jun; 7(6):. PubMed ID: 29757368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
    Ye Y; Li SL; Wang SY
    PLoS One; 2018; 13(8):e0198055. PubMed ID: 30138363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 10 differently expressed lncRNAs as prognostic biomarkers for prostate adenocarcinoma.
    Wu ZY; Wang SG; Li Q; Zhao QS; Shao MM
    Math Biosci Eng; 2019 Dec; 17(3):2037-2047. PubMed ID: 32233522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNAs in prostate cancer: overview and clinical implications.
    Malik B; Feng FY
    Asian J Androl; 2016; 18(4):568-74. PubMed ID: 27072044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer RNAs and regulated transcriptional programs.
    Lam MT; Li W; Rosenfeld MG; Glass CK
    Trends Biochem Sci; 2014 Apr; 39(4):170-82. PubMed ID: 24674738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long non-coding RNAs and prostate cancer.
    Misawa A; Takayama KI; Inoue S
    Cancer Sci; 2017 Nov; 108(11):2107-2114. PubMed ID: 28796922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive Characterization of Androgen-Responsive lncRNAs Mediated Regulatory Network in Hormone-Related Cancers.
    Wang D; Li M; Li J; Wan X; Huang Y; Wang C; Zhang P; Xu Y; Kong Z; Lu Y; Wang X; Liu C; Ji C; Li L
    Dis Markers; 2020; 2020():8884450. PubMed ID: 33082888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNAs in prostate cancer: Biological and clinical implications.
    Das R; Feng FY; Selth LA
    Mol Cell Endocrinol; 2019 Jan; 480():142-152. PubMed ID: 30391670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.